Literature DB >> 17624496

New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Mahlon D Johnson1, Burak Sade, Michael T Milano, Joung H Lee, Steven A Toms.   

Abstract

Skull base, including optic nerve, cavernous sinus, clival and foramen magnum tumors represent a major challenge for neurosurgeons and neuro-oncologists. Growth regulatory signaling pathways for these tumors are of increasing interest as potential targets for new chemotherapy. Those differentially activated in various grades of meningiomas are currently being identified as well. This article reviews some recent findings pathways that appear to regulate meningioma growth. Potential targets for novel therapies are also discussed.

Entities:  

Mesh：

Year:  2007        PMID： 17624496     DOI： 10.1007/s11060-007-9434-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  157 in total

1.  Intensity-modulated stereotactic radiotherapy vs. stereotactic conformal radiotherapy for the treatment of meningioma located predominantly in the skull base.

Authors:  Brigitta G Baumert; Ian A Norton; J Bernard Davis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-10-01       Impact factor: 7.038

2.  Fractionated stereotactic radiotherapy in the treatment of exclusive cavernous sinus meningioma: functional outcome, local control, and tolerance.

Authors:  Marta Brell; Salvador Villà; Pilar Teixidor; Anna Lucas; Enric Ferrán; Susanna Marín; Juan Jose Acebes
Journal:  Surg Neurol       Date:  2006-01

3.  Platelet-derived growth factor-BB and thrombin activate phosphoinositide 3-kinase and protein kinase B: role in mediating airway smooth muscle proliferation.

Authors:  T R Walker; S M Moore; M F Lawson; R A Panettieri; E R Chilvers
Journal:  Mol Pharmacol       Date:  1998-12       Impact factor: 4.436

4.  Changing treatment strategy of cavernous sinus meningiomas: experience of a single institution.

Authors:  M Necmettin Pamir; Türker Kiliç; Fatih Bayrakli; Selçuk Peker
Journal:  Surg Neurol       Date:  2005

5.  Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells.

Authors:  Mahlon D Johnson; Evelyn Okedli; Ann Woodard; Steven A Toms; George S Allen
Journal:  J Neurosurg       Date:  2002-09       Impact factor: 5.115

6.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells.

Authors:  M Sun; G Wang; J E Paciga; R I Feldman; Z Q Yuan; X L Ma; S A Shelley; R Jove; P N Tsichlis; S V Nicosia; J Q Cheng
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

7.  Posterior fossa meningiomas: surgical experience in 161 cases.

Authors:  F Roberti; L N Sekhar; C Kalavakonda; D C Wright
Journal:  Surg Neurol       Date:  2001-07

8.  Radiosurgical management of benign cavernous sinus tumors: dose profiles and acute complications.

Authors:  J C Chen; S L Giannotta; C Yu; Z Petrovich; M L Levy; M L Apuzzo
Journal:  Neurosurgery       Date:  2001-05       Impact factor: 4.654

9.  Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.

Authors:  U M Schrell; M G Rittig; M Anders; U H Koch; R Marschalek; F Kiesewetter; R Fahlbusch
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

10.  Epidermal growth factor receptor expression in 72 meningiomas.

Authors:  N R Jones; M L Rossi; M Gregoriou; J T Hughes
Journal:  Cancer       Date:  1990-07-01       Impact factor: 6.860
View more
  10 in total

1.  Light at the end of the tunnel: towards an effective drug therapy for surgery- and radiation-refractory meningioma.

Authors:  Christine Marosi
Journal:  Neuro Oncol       Date:  2014-11-04       Impact factor: 12.300

2.  Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism.

Authors:  Mahlon D Johnson; Mary O'Connell; Webster Pilcher
Journal:  J Neurooncol       Date:  2010-07-02       Impact factor: 4.130

3.  Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.

Authors:  Peter Horak; Adelheid Wöhrer; Marco Hassler; Johannes Hainfellner; Matthias Preusser; Christine Marosi
Journal:  J Neurooncol       Date:  2012-05-20       Impact factor: 4.130

Review 4.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

5.  Predictors of Treatment Response and Survival Outcomes in Meningioma Recurrence with Atypical or Anaplastic Histology.

Authors:  Muhammad O Chohan; Christopher T Ryan; Ranjodh Singh; Ryan M Lanning; Anne S Reiner; Marc K Rosenblum; Viviane Tabar; Philip H Gutin
Journal:  Neurosurgery       Date:  2018-06-01       Impact factor: 4.654

Review 6.  Management options for cavernous sinus meningiomas.

Authors:  Michael T Walsh; William T Couldwell
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

7.  Gamma knife radiosurgery of meningiomas involving the foramen magnum.

Authors:  Robert M Starke; James H Nguyen; Davis L Reames; Jessica Rainey; Jason P Sheehan
Journal:  J Craniovertebr Junction Spine       Date:  2010-01

8.  Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.

Authors:  Mahlon D Johnson; Mary J O'Connell; Kevin Walter
Journal:  BMC Complement Altern Med       Date:  2013-11-04       Impact factor: 3.659

9.  Human epidermal growth factor receptor 2/neu protein expression in meningiomas: An immunohistochemical study.

Authors:  Ramesh Babu Telugu; Amit Kumar Chowhan; Nandyala Rukmangadha; Rashmi Patnayak; Bobbidi Venkata Phaneendra; Bodapati Chandra Mowliswara Prasad; Mandyam Kumaraswamy Reddy
Journal:  J Neurosci Rural Pract       Date:  2016 Oct-Dec

Review 10.  Emerging Medical Treatments for Meningioma in the Molecular Era.

Authors:  Fares Nigim; Hiroaki Wakimoto; Ekkehard M Kasper; Linda Ackermans; Yasin Temel
Journal:  Biomedicines       Date:  2018-08-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.